Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis

Chen Y-L., Gutowska-Owsiak D., Hardman CS., Westmoreland M., MacKenzie T., Cifuentes L., Waithe D., Lloyd-Lavery A., Marquette A., Londei M., Ogg G.

First-in-class clinical trial of IL-33 blockade shows inhibition of neutrophil migration into human skin and modulates atopic dermatitis symptoms.

DOI

10.1126/scitranslmed.aax2945

Type

Journal article

Publisher

American Association for the Advancement of Science (AAAS)

Publication Date

2019-10-23T00:00:00+00:00

Volume

11

Permalink More information Close